Linked Life Data

18087660

Source:http://linkedlifedata.com/resource/pubmed/id/18087660

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7
pubmed:dateCreated
2008-6-2
pubmed:abstractText
Postmenopausal women with osteoporosis received 75 mg risedronate on two consecutive days each month or 5 mg daily for 12 months. Changes in bone mineral density and bone turnover markers were similar between treatments. Risedronate 75 mg twice monthly was effective and safe suggesting a new, convenient dosing schedule.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0937-941X
pubmed:author
pubmed:issnType
Print
pubmed:volume
19
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1039-45
pubmed:dateRevised
2010-5-10
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results.
pubmed:affiliation
University of Lyon and INSERM Research Unit 831, Lyon, France. delmas@lyon.inserm.fr
pubmed:publicationType
Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study, Clinical Trial, Phase III